Ischemic PreconditioningConBISNCT03380663
Conditioning Based Intervention Strategies
A study testing Remote Ischemic Conditioning (RIC) in people with Ischemic Preconditioning, run by University of Aarhus at 1 site in Denmark.
Trial summary
The overall objective of this study is to uncover and utilize the mechanisms behind the activation of endogenous organ protection by remote ischemic conditioning (RIC), high intensity traditional resistance training (TRT) and low intensity blood flow restricted resistance exercise (BFRE) with the perspective of… Read more about this study
- Who is it for?
- Ages 18 to 80 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Ischemic Preconditioning
- What is being tested?
- Remote Ischemic Conditioning (RIC)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 84 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Sep 2016to 1 Jul 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Able to understand the written and spoken information and to give informed consent for inclusion.
- Age between 18 and 80 years
- Able to sit in a knee extension machine
- Able to deliver muscle biopsies
- Able to train 3 times per week during a 6-week period
- Chronic congestive ischemic heart failure
Show all 9Show fewer
- LV ejection fraction ≤45%
- NYHA function class II-IV
- See general criteria for inclusion
Who cannot join
- Myocardial infarction
- Angina pectoris
- Pregnancy
- Diabetes mellitus
- Peripheral neuropathy
- Dialysis treatment
Show all 23Show fewer
- Severe peripheral arterial disease
- Concomitant acute life threatening medical condition
- Medications known to modify the effect of ischemic conditioning such as cyclosporin and glibenclamide.
- Recent cardiovascular hospitalization (within last 30 days)
- Intracranial aneurisms, arteriovenous malformation, cerebral neoplasm or abscess.
- Myocardial infarction
- Angina pectoris
- Severe arterial hypertension (≥ 180/≥ 110 mmHg) or moderate arterial hypertension (160-179/100-109) despite medical treatment.
- Moderate to severe cardiac valve disease
- Beta blocker medication
- Moderate or severe chronic obstructive pulmonary disease
- Decreased kidney function - eGFR < 60 ml/min.
- Criteria for stopping the intervention or investigations
- Severe discomfort and/or by request of the participant.
- Safety considerations as assessed by the investigator.
- Withdrawal of informed consent.
- Not able to fulfill the protocol.
Trial locations and contacts
1 site in 1 country.
Denmark1 site, 1 recruiting
- Recruiting
Aarhus University
Aarhus, 8000
Frank Vincenzo de Paoli, MD, PhD, +45 6146 0880, fdp@biomed.au.dk
Bent Roni Nielsen, MD, PhD, +45 5121 9363, bent.nils@midt.rm.dk
About this study
Official title: Conditioning Based Intervention Strategies - ConBIS. A Research Study on the Potential of Remote Conditioning for Activation of Endogenous Organ Protection and the Underlying Molecular Mechanisms
The overall objective of this study is to uncover and utilize the mechanisms behind the activation of endogenous organ protection by remote ischemic conditioning (RIC), high intensity traditional resistance training (TRT) and low intensity blood flow restricted resistance exercise (BFRE) with the perspective of defining their applicability for immediate organ protection in ischemia-reperfusion injury (acute conditioning) and subsequent tissue repair (chronic conditioning) during a prolonged recovery period. This objective will be achieved by studying which and how molecular pathways underlying these protective mechanisms are shared and can be transferred to treat medical conditions. A specific focus is the roles of EVs and miRNAs. Another objective is to explore how exercise training with and without ischemia can counteract muscle wasting.
Read the detailed description
Background
Clinical background - ischemia related and inflammatory conditions The pandemic of cardiovascular disease has immense negative effects on global population health and life expectancy. The most detrimental acute ischemic events are myocardial infarction and stroke. Organ failure caused by ischemia-reperfusion syndromes such as stroke and myocardial infarction constitutes the leading cause of death globally and carry a vast socio-economical burden. Overall, 17 million people worldwide are estimated to die from cardiovascular diseases (7.4 million from ischemic heart disease and 6.7 million from stroke). Attempts to modify risk factor and life style related growth in cardiovascular disease are important and have been successful in some parts of the world, but improved treatment of acute and chronic cardiovascular disease is crucial to alleviate the disease burden.
In acute ischemic conditions such as myocardial infarction and stroke, early and successful restoration of tissue perfusion following an ischemic event is the most effective strategy to reduce tissue injury and improve clinical outcome, but reperfusion may induce further tissue damage itself, so-called reperfusion injury. Although reperfusion strategies continue to progress with improved logistics and medical treatment, even optimal acute reperfusion treatment may leave patients with chronic ischemic disease. Actually, as initial survival has improved due to improvements in acute reperfusion therapy, the number of patients with chronic ischemic heart disease is growing globally (more than 35 million people worldwide suffering from heart failure). Collectively, patients with heart failure have a poorer 5-year survival rate than patients with most types of cancer. However, the development of effective drugs to target the detrimental effects of reperfusion injury itself has proven to be a challenge. Several pharmacologic strategies showing convincing effects in animal models of ischemia-reperfusion injury have failed to translate into clinical benefit.
A key feature of heart failure caused by chronic ischemic heart disease is inflammation, which shares mechanisms with other inflammatory conditions such as inflammatory bowel disease and ankylosing spondylitis. Further debilitating, heart failure also exerts a negative effect on habitual physical activity and skeletal muscle tissue health, producing multiple detrimental effects on whole-body metabolism and mobility. A common underlying mechanistic trait of these processes could be regulation by circulating small non-coding RNAs (micro RNAs or miRNAs/miRs).
Scientific background Remote ischemic conditioning The main prognostic determinant of outcome in acute myocardial infarction is the extent of tissue damage (infarct size), which is determined not only by the duration of ischemia but also by injury caused by reperfusion injury. Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff. With few exceptions, RIC has consistently been shown to exert powerful protection against ischemia-reperfusion injury in the heart, brain, kidneys, lungs, and liver in animal models, and RIC has successfully been translated into clinical use. A specific advantage of RIC is its easy applicability during ongoing ischemia of the target organ, which has been exploited in animal models and humans to show that RIC reduces injury during evolving myocardial infarction and stroke.
While the mediators and mechanisms of RIC remain to be identified, RIC has been shown to 1) induce cytoprotection, 2) improve endothelial function and microcirculation, and 3) modify inflammation - all three key players in the pathology behind heart failure - suggesting a potentially powerful tool to simultaneously counteract detrimental biological processes involved in the development of heart failure. RIC may have further potential because continued RIC after myocardial infarction seems to induce sustained benefits during the following adverse remodeling of the heart. The anti-inflammatory effects may be of importance in other conditions involving acute or chronic inflammation.
Ischemia and conditioning with blood flow restricted resistance exercise Exercise is traditionally categorized and practiced as either oxygen-demanding aerobic endurance exercise with effect on metabolic properties or mechanically stressing resistance exercise with effect on contractile properties. In addition to local myocellular effects, exercise appears to promote molecular inter-organ communication. Indeed, recent studies have demonstrated the ability of traditional exercise regimens to protect against e.g. myocardial ischemia-reperfusion injury and also to improve cognitive function, hence the conception that "exercise is medicine". Studies suggest that these remote effects are induced by myocellular production of circulatory mediators to influence tissues of remote organs. Exercise-induced muscle-organ cross-talk may, similar to RIC, rely on extracellular vesicle derived miRNA (see next paragraph). Supporting such a notion, is the finding that high intensity traditional resistance exercise evokes increased transcription of miR133b, since miR133b has recently been demonstrated to promote recovery after stroke via transfer of exosome-enriched extracellular particles. However, high intensity traditional exercise can produce muscle injury and may therefore not comply with exercise in patients with cardiovascular or other chronic muscle wasting diseases.
A novel approach may be offered by Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery. By this mechanically very gentle approach, muscle accretion similar to that of high intensity traditional resistance training (TRT) can be achieved, possibly due to acceleration of metabolic build-up or activation of muscle stem cells. Interestingly, new results by us, demonstrate that BFRE can mediate long-lasting preconditioning effects in muscle. Since low-intensity BFRE mimics events of both traditional high intensity resistance exercise (occlusion-reperfusion) and traditional aerobe exercise (hypoxia), BFRE can be speculated to drive health beneficial metabolic as well as anabolic adaptations in the muscle. Based on its resemblance to RIC, BFRE likely also affect remote tissues and infer remote organ protection. The extent to which RIC and exercise regimens may share or overlap or differ mechanistically - and potentially exert additive effects - is unknown, but application of BFRE entails highly promising clinical perspectives.
Micro RNA signaling Circulating extracellular vesicles (EVs) are small particles released from plasma membranes from almost all cell types. These EVs seem to act as transport systems in the body carrying a cargo of signaling substances including miRNAs. miRNAs are also effector molecules in ischemic events, e.g. myocardial miRNA144 (miR144) levels are reduced by ischemic reperfusion injury (IR injury), which is attenuated by RIC. RIC also induces increased circulatory EV levels, while EVs enriched with miR22 and miR451 from anoxic cultured MSCs and cardiomycyte progenitor cells mitigate cardiac injury. Potentially, treatment with specific miRNA loaded into EVs may provide protection against acute and chronic effects of myocardial ischemia-reperfusion injury in patients [19]. EVs are also believed to contain other substances including anti-inflammatory components acting in synergy with miRNA to exert the full effect of the signaling cascade.
Objectives The overall objective of this study is to uncover and utilize the mechanisms behind the activation of endogenous organ protection by remote ischemic conditioning (RIC), high intensity traditional resistance training (TRT) and low intensity blood flow restricted resistance exercise (BFRE) with the perspective of defining their applicability for immediate organ protection in ischemia-reperfusion injury (acute conditioning) and subsequent tissue repair (chronic conditioning) during a prolonged recovery period. This objective will be achieved by studying which and how molecular pathways underlying these protective mechanisms are shared and can be transferred to treat medical conditions. A specific focus is the roles of EVs and miRNAs. Another objective is to explore how exercise training with and without ischemia can counteract muscle wasting.
Hypotesis
The overall hypothesis of the proposal is that RIC and exercise potentiated by BFRE and TRT release circulating protective mediators that exert immediate protective effects against IR injury as well as promote beneficial repair during subsequent tissue rebuilding and in chronic inflammatory conditions. Specifically, we will test the following hypotheses:
- RIC, BFRE and TRT share organ protecting and anti-inflammatory properties induced through common miRNA signaling pathways
- Long lasting effect of RIC, BFRE and TRT can be achieved by repeated treatment, and the chronic effects include anti-inflammatory and anti-ischemic properties of clinical relevance by:
- Improving ventricular function and reduce symptoms in patients with heart failure and chronic ischemic heart disease (individual sub-study, a separate application has been submitted to and approved by De Videnskabsetiske Komitéer).
- Counteracting muscle wasting in patients with heart failure.
- BFRE is a more effective mean to increase muscle mass, muscle power and muscle function compared to TRT.
- Non-conditioned EVs can be loaded with RIC, BFRE and specific miRNA, in vitro and exert immediate protective effects against IR injury upon intravenous injection (future sub-study)
- Conditions
- Ischemic Preconditioning
- Being tested
- Remote Ischemic Conditioning (RIC)
- Keywords
- blood flow restricted resistance exercise, remote ischemic conditioning, miRNA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote Ischemic Conditioning (RIC)Procedure or surgery
Also called Blood Flow Restricted resistance Exercise (BFRE), Traditional Resistance Training (TRT)
Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.
High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
| Study group | Role | What they receive |
|---|---|---|
| RIC - Healthy | Active comparator | Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet. Receives: Procedure: Remote Ischemic Conditioning (RIC) |
| RIC - HF | Active comparator | Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet. Receives: Procedure: Remote Ischemic Conditioning (RIC) |
| BFRE - Healthy | Active comparator | Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated). Receives: Procedure: Remote Ischemic Conditioning (RIC) |
| BFRE - HF | Active comparator | Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated). Receives: Procedure: Remote Ischemic Conditioning (RIC) |
| TRT - Healthy | Active comparator | Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes). Receives: Procedure: Remote Ischemic Conditioning (RIC) |
| Control - Healthy | No intervention | No intervention. |
| Control - HF | No intervention | No intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in miRNA and EV content in blood samples
Analyzing miRNA sequences
Measured: 6 Weeks
Secondary outcomes (5)
Effects on muscle endurance
Number of repetitions in curl machine and mitochondrial oxidative capacity
Measured: 6 weeks
Effects on inflammatory state
Changes in cytokines
Measured: 6 weeks
Changes in skeletal muscle myofibrillar and mitochondrial protein synthesis
Histochemical examination
Measured: 6 weeks
Protection against IR injury in isolated rat/rabbit hearts and isolated cells
Histological examination
Measured: 6 weeks
Changes in skeletal muscle growth and strength
Muscle strength measurement - force
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2017
- Study start1 Sep 2016
- Primary completion1 Oct 2018 (estimated)
- Study completion1 Jul 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Ischemic PreconditioningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A multi-center randomized control study, including single-treatment and repeated treatment trials on individuals suffering from heart failure and healthy control subjects.
- Masking
- None (open label)
- Enrolment
- 84 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hans Erik Bøtker, MD, PhD, Study director, Department of Clinical Medicine, Department of Cardiological Medicine, Aarhus University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03380663
- Sponsor's protocol ID
- ConBIS
- Acronym
- ConBIS
- Status last verified
- Aug 2017
- First submitted
- 23 Aug 2017
- Last updated
- 22 Dec 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lassen TR, Just J, Hjortbak MV, Jespersen NR, Stenz KT, Gu T, Yan Y, Su J, Hansen J, Baek R, Jorgensen MM, Nyengaard JR, Kristiansen SB, Drasbek KR, Kjems J, Botker HE. Cardioprotection by remote ischemic conditioning is transferable by plasma and mediated by extracellular vesicles. Basic Res Cardiol. 2021 Mar 10;116(1):16. doi: 10.1007/s00395-021-00856-w.
PubMed 33689033Groennebaek T, Sieljacks P, Nielsen R, Pryds K, Jespersen NR, Wang J, Carlsen CR, Schmidt MR, de Paoli FV, Miller BF, Vissing K, Botker HE. Effect of Blood Flow Restricted Resistance Exercise and Remote Ischemic Conditioning on Functional Capacity and Myocellular Adaptations in Patients With Heart Failure. Circ Heart Fail. 2019 Dec;12(12):e006427. doi: 10.1161/CIRCHEARTFAILURE.119.006427. Epub 2019 Dec 13.
PubMed 31830830
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Conditioning Based Intervention Strategies - ConBIS. A Research Study on the Potential of Remote Conditioning for Activation of Endogenous Organ Protection and the Underlying Molecular Mechanisms
- ClinicalTrials.gov ID
- NCT03380663
- Acronym / sponsor ID
- ConBIS / ConBIS
- Conditions
- Ischemic Preconditioning
- Keywords
- blood flow restricted resistance exercise, remote ischemic conditioning, miRNA
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 84 participants (estimated)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Study start
- 1 Sep 2016 (actual)
- Primary completion
- 1 Oct 2018 (estimated)
- Study completion
- 1 Jul 2019 (estimated)
- First posted
- 21 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall objective of this study is to uncover and utilize the mechanisms behind the activation of endogenous organ protection by remote ischemic conditioning (RIC), high intensity traditional resistance training (TRT) and low intensity blood flow restricted resistance exercise (BFRE) with the perspective of defining their applicability for immediate organ protection in ischemia-reperfusion injury (acute conditioning) and subsequent tissue repair (chronic conditioning) during a prolonged recovery period. This objective will be achieved by studying which and how molecular pathways underlying these protective mechanisms are shared and can be transferred to treat medical conditions. A specific focus is the roles of EVs and miRNAs. Another objective is to explore how exercise training with and without ischemia can counteract muscle wasting.
Detailed description
Background
Clinical background - ischemia related and inflammatory conditions The pandemic of cardiovascular disease has immense negative effects on global population health and life expectancy. The most detrimental acute ischemic events are myocardial infarction and stroke. Organ failure caused by ischemia-reperfusion syndromes such as stroke and myocardial infarction constitutes the leading cause of death globally and carry a vast socio-economical burden. Overall, 17 million people worldwide are estimated to die from cardiovascular diseases (7.4 million from ischemic heart disease and 6.7 million from stroke). Attempts to modify risk factor and life style related growth in cardiovascular disease are important and have been successful in some parts of the world, but improved treatment of acute and chronic cardiovascular disease is crucial to alleviate the disease burden.
In acute ischemic conditions such as myocardial infarction and stroke, early and successful restoration of tissue perfusion following an ischemic event is the most effective strategy to reduce tissue injury and improve clinical outcome, but reperfusion may induce further tissue damage itself, so-called reperfusion injury. Although reperfusion strategies continue to progress with improved logistics and medical treatment, even optimal acute reperfusion treatment may leave patients with chronic ischemic disease. Actually, as initial survival has improved due to improvements in acute reperfusion therapy, the number of patients with chronic ischemic heart disease is growing globally (more than 35 million people worldwide suffering from heart failure). Collectively, patients with heart failure have a poorer 5-year survival rate than patients with most types of cancer. However, the development of effective drugs to target the detrimental effects of reperfusion injury itself has proven to be a challenge. Several pharmacologic strategies showing convincing effects in animal models of ischemia-reperfusion injury have failed to translate into clinical benefit.
A key feature of heart failure caused by chronic ischemic heart disease is inflammation, which shares mechanisms with other inflammatory conditions such as inflammatory bowel disease and ankylosing spondylitis. Further debilitating, heart failure also exerts a negative effect on habitual physical activity and skeletal muscle tissue health, producing multiple detrimental effects on whole-body metabolism and mobility. A common underlying mechanistic trait of these processes could be regulation by circulating small non-coding RNAs (micro RNAs or miRNAs/miRs).
Scientific background Remote ischemic conditioning The main prognostic determinant of outcome in acute myocardial infarction is the extent of tissue damage (infarct size), which is determined not only by the duration of ischemia but also by injury caused by reperfusion injury. Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff. With few exceptions, RIC has consistently been shown to exert powerful protection against ischemia-reperfusion injury in the heart, brain, kidneys, lungs, and liver in animal models, and RIC has successfully been translated into clinical use. A specific advantage of RIC is its easy applicability during ongoing ischemia of the target organ, which has been exploited in animal models and humans to show that RIC reduces injury during evolving myocardial infarction and stroke.
While the mediators and mechanisms of RIC remain to be identified, RIC has been shown to 1) induce cytoprotection, 2) improve endothelial function and microcirculation, and 3) modify inflammation - all three key players in the pathology behind heart failure - suggesting a potentially powerful tool to simultaneously counteract detrimental biological processes involved in the development of heart failure. RIC may have further potential because continued RIC after myocardial infarction seems to induce sustained benefits during the following adverse remodeling of the heart. The anti-inflammatory effects may be of importance in other conditions involving acute or chronic inflammation.
Ischemia and conditioning with blood flow restricted resistance exercise Exercise is traditionally categorized and practiced as either oxygen-demanding aerobic endurance exercise with effect on metabolic properties or mechanically stressing resistance exercise with effect on contractile properties. In addition to local myocellular effects, exercise appears to promote molecular inter-organ communication. Indeed, recent studies have demonstrated the ability of traditional exercise regimens to protect against e.g. myocardial ischemia-reperfusion injury and also to improve cognitive function, hence the conception that "exercise is medicine". Studies suggest that these remote effects are induced by myocellular production of circulatory mediators to influence tissues of remote organs. Exercise-induced muscle-organ cross-talk may, similar to RIC, rely on extracellular vesicle derived miRNA (see next paragraph). Supporting such a notion, is the finding that high intensity traditional resistance exercise evokes increased transcription of miR133b, since miR133b has recently been demonstrated to promote recovery after stroke via transfer of exosome-enriched extracellular particles. However, high intensity traditional exercise can produce muscle injury and may therefore not comply with exercise in patients with cardiovascular or other chronic muscle wasting diseases.
A novel approach may be offered by Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery. By this mechanically very gentle approach, muscle accretion similar to that of high intensity traditional resistance training (TRT) can be achieved, possibly due to acceleration of metabolic build-up or activation of muscle stem cells. Interestingly, new results by us, demonstrate that BFRE can mediate long-lasting preconditioning effects in muscle. Since low-intensity BFRE mimics events of both traditional high intensity resistance exercise (occlusion-reperfusion) and traditional aerobe exercise (hypoxia), BFRE can be speculated to drive health beneficial metabolic as well as anabolic adaptations in the muscle. Based on its resemblance to RIC, BFRE likely also affect remote tissues and infer remote organ protection. The extent to which RIC and exercise regimens may share or overlap or differ mechanistically - and potentially exert additive effects - is unknown, but application of BFRE entails highly promising clinical perspectives.
Micro RNA signaling Circulating extracellular vesicles (EVs) are small particles released from plasma membranes from almost all cell types. These EVs seem to act as transport systems in the body carrying a cargo of signaling substances including miRNAs. miRNAs are also effector molecules in ischemic events, e.g. myocardial miRNA144 (miR144) levels are reduced by ischemic reperfusion injury (IR injury), which is attenuated by RIC. RIC also induces increased circulatory EV levels, while EVs enriched with miR22 and miR451 from anoxic cultured MSCs and cardiomycyte progenitor cells mitigate cardiac injury. Potentially, treatment with specific miRNA loaded into EVs may provide protection against acute and chronic effects of myocardial ischemia-reperfusion injury in patients [19]. EVs are also believed to contain other substances including anti-inflammatory components acting in synergy with miRNA to exert the full effect of the signaling cascade.
Objectives The overall objective of this study is to uncover and utilize the mechanisms behind the activation of endogenous organ protection by remote ischemic conditioning (RIC), high intensity traditional resistance training (TRT) and low intensity blood flow restricted resistance exercise (BFRE) with the perspective of defining their applicability for immediate organ protection in ischemia-reperfusion injury (acute conditioning) and subsequent tissue repair (chronic conditioning) during a prolonged recovery period. This objective will be achieved by studying which and how molecular pathways underlying these protective mechanisms are shared and can be transferred to treat medical conditions. A specific focus is the roles of EVs and miRNAs. Another objective is to explore how exercise training with and without ischemia can counteract muscle wasting.
Hypotesis
The overall hypothesis of the proposal is that RIC and exercise potentiated by BFRE and TRT release circulating protective mediators that exert immediate protective effects against IR injury as well as promote beneficial repair during subsequent tissue rebuilding and in chronic inflammatory conditions. Specifically, we will test the following hypotheses:
- RIC, BFRE and TRT share organ protecting and anti-inflammatory properties induced through common miRNA signaling pathways
- Long lasting effect of RIC, BFRE and TRT can be achieved by repeated treatment, and the chronic effects include anti-inflammatory and anti-ischemic properties of clinical relevance by:
- Improving ventricular function and reduce symptoms in patients with heart failure and chronic ischemic heart disease (individual sub-study, a separate application has been submitted to and approved by De Videnskabsetiske Komitéer).
- Counteracting muscle wasting in patients with heart failure.
- BFRE is a more effective mean to increase muscle mass, muscle power and muscle function compared to TRT.
- Non-conditioned EVs can be loaded with RIC, BFRE and specific miRNA, in vitro and exert immediate protective effects against IR injury upon intravenous injection (future sub-study)
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 7
- Model description
- A multi-center randomized control study, including single-treatment and repeated treatment trials on individuals suffering from heart failure and healthy control subjects.
| Arm | Type | Receives |
|---|---|---|
| RIC - Healthy | Active comparator | Procedure: Remote Ischemic Conditioning (RIC)Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet. |
| RIC - HF | Active comparator | Procedure: Remote Ischemic Conditioning (RIC)Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet. |
| BFRE - Healthy | Active comparator | Procedure: Remote Ischemic Conditioning (RIC)Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated). |
| BFRE - HF | Active comparator | Procedure: Remote Ischemic Conditioning (RIC)Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated). |
| TRT - Healthy | Active comparator | Procedure: Remote Ischemic Conditioning (RIC)Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes). |
| Control - Healthy | No intervention | –No intervention. |
| Control - HF | No intervention | –No intervention. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Able to understand the written and spoken information and to give informed consent for inclusion.
- Age between 18 and 80 years
- Able to sit in a knee extension machine
- Able to deliver muscle biopsies
- Able to train 3 times per week during a 6-week period
Key exclusion criteria (23 listed)
- Myocardial infarction
- Angina pectoris
- Pregnancy
- Diabetes mellitus
- Peripheral neuropathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote Ischemic Conditioning (RIC)Also: Blood Flow Restricted resistance Exercise (BFRE), Traditional Resistance Training (TRT)Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery. High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes). | Procedure or surgery | BFRE - HF, BFRE - Healthy, RIC - HF, RIC - Healthy, TRT - Healthy |
Primary outcome
Changes in miRNA and EV content in blood samples
Time frame: 6 Weeks
Analyzing miRNA sequences
5 secondary outcomes
Effects on muscle endurance
Time frame: 6 weeks
Effects on inflammatory state
Time frame: 6 weeks
Changes in skeletal muscle myofibrillar and mitochondrial protein synthesis
Time frame: 6 weeks
Protection against IR injury in isolated rat/rabbit hearts and isolated cells
Time frame: 6 weeks
Changes in skeletal muscle growth and strength
Time frame: 6 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2017.
- Derived from this study: PubMed 33689033Lassen TR, Just J, Hjortbak MV, Jespersen NR, Stenz KT, Gu T, Yan Y, Su J, Hansen J, Baek R, Jorgensen MM, Nyengaard JR, Kristiansen SB, Drasbek KR, Kjems J, Botker HE. Cardioprotection by remote ischemic conditioning is transferable by plasma and mediated by extracellular vesicles. Basic Res Cardiol. 2021 Mar 10;116(1):16. doi: 10.1007/s00395-021-00856-w.
- Derived from this study: PubMed 31830830Groennebaek T, Sieljacks P, Nielsen R, Pryds K, Jespersen NR, Wang J, Carlsen CR, Schmidt MR, de Paoli FV, Miller BF, Vissing K, Botker HE. Effect of Blood Flow Restricted Resistance Exercise and Remote Ischemic Conditioning on Functional Capacity and Myocellular Adaptations in Patients With Heart Failure. Circ Heart Fail. 2019 Dec;12(12):e006427. doi: 10.1161/CIRCHEARTFAILURE.119.006427. Epub 2019 Dec 13.
- Individual participant dataSharing planned: No
Related trials for Ischemic Preconditioning
Recruiting
A Multicenter, Prospective, Double-blind, Randomized Controlled Study on the Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
Moya Moya Disease, Moyamoya Syndrome
Recruiting
Effects of Remote Ischemic Preconditioning at Different Time Phases in Patients Undergoing Heart Valve Surgery
Heart Valve Surgery, Acute Kidney Injury
Recruiting
Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)
Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
Aortic Dissection Type A
Not yet recruiting
Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning
Aneurysmal Subarachnoid Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hans Erik Bøtker, MD, PhD study director
Department of Clinical Medicine, Department of Cardiological Medicine, Aarhus University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote Ischemic Conditioning (RIC) in people with Ischemic Preconditioning, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Frank de Paoli, MD, PhD (+45 61460880, fdp@biomed.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in miRNA and EV content in blood samples (time frame: 6 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03380663, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2017.